Selected article for: "clinical feature and disease severity"

Author: Lingeswaran, Malavika; Goyal, Taru; Ghosh, Raghumoy; Suri, Smriti; Mitra, Prasenjit; Misra, Sanjeev; Sharma, Praveen
Title: Inflammation, Immunity and Immunogenetics in COVID-19: A Narrative Review
  • Cord-id: zy9lb7d9
  • Document date: 2020_6_6
  • ID: zy9lb7d9
    Snippet: The novel Coronavirus Disease 2019 (COVID-19), that began in Wuhan Province, China was labelled as an International Public Health Emergency on January 30, 2020 and later was declared a pandemic by the World Health Organisation (WHO) on March 11, 2020. The causative agent, SARS-CoV-2 was the third coronavirus responsible for causing major disease outbreaks in human population after Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS) caused by SARS-CoV and MERS-CoV
    Document: The novel Coronavirus Disease 2019 (COVID-19), that began in Wuhan Province, China was labelled as an International Public Health Emergency on January 30, 2020 and later was declared a pandemic by the World Health Organisation (WHO) on March 11, 2020. The causative agent, SARS-CoV-2 was the third coronavirus responsible for causing major disease outbreaks in human population after Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS) caused by SARS-CoV and MERS-CoV respectively. The patients of COVID-19 present with a clinical feature resembling mild form of viral pneumonia which in certain cases progress to a severe form characterised by adult respiratory distress syndrome (ARDS) and/or multiorgan failure leading to death. The transition from mild to severe form of COVID-19 is affected by a lot of factors like age, co-morbidities etc. In the absence of an absolute cure, it is essential to explore the molecular pathogenesis of the disease to identify people at risk of developing severity so that alternative treatment modalities may be planned. The aim of this review is to provide an update on the general characteristics of SARS-CoV-2 and highlight the inflammatory changes and immune dysregulation that may help in identification of molecular predictors of disease severity.

    Search related documents:
    Co phrase search for related documents
    • absolute number and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
    • absolute number and acute respiratory distress syndrome: 1, 2, 3, 4
    • absolute number and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
    • absolute number and adaptive immune cell: 1
    • absolute number and adaptive immune system: 1, 2
    • absolute number and adaptive innate: 1, 2, 3, 4
    • accessory protein and activation differentiation: 1
    • accessory protein and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • accessory protein and acute respiratory distress syndrome: 1, 2, 3
    • accessory protein and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • activate cytokine and acute respiratory: 1, 2, 3, 4
    • activate cytokine and acute respiratory syndrome: 1, 2, 3, 4
    • activate cytokine and adaptive innate: 1
    • activation differentiation and acute respiratory distress syndrome: 1, 2, 3
    • activation differentiation and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • activation differentiation and adaptive immune cell: 1
    • activation differentiation and adaptive immune system: 1, 2
    • activation differentiation and adaptive immunity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • activation differentiation and adaptive innate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10